CAPLIPOINT - Technical Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Technical Rating: 3.8

Let’s break down the technical setup for Caplin Point Laboratories (CAPLIPOINT) 💊📊

📉 Trend & Price Structure

Current Price (₹2,086) sits above both 50 DMA (₹2,061) and 200 DMA (₹1,987) ➤ confirms short-term uptrend

Price is nearly 21% below 52-week high (₹2,641), but holding above key support ➤ implies base-building post correction

Overall price action forming a sideways-to-rising wedge, hinting at potential breakout if momentum improves

📊 Indicator Snapshot

RSI (52.6)

Slightly bullish ➤ above neutral zone (50), could strengthen with price push

No overbought signals yet, allowing room for upside

MACD (4.04)

Positive and rising ➤ suggests bullish momentum is developing

A crossover above previous MACD peak would confirm continuation

Volume

Slightly below 1Wk average ➤ moderate market interest

Needs volume surge to validate any breakout moves

Bollinger Bands

Price approaching upper band ➤ volatility may expand; watch for squeeze breakout

⚡ Short-Term Momentum Outlook

Indicators reflect emerging bullish momentum, though volume is yet to catch up

Momentum supported by consistent profit performance and improving investor sentiment (FII ↑ 0.43%)

🎯 Entry & Exit Zones

Strategy Type Price Zone (₹) Rationale

Entry (Support Buy) ₹2,050 - ₹2,070 Zone near 50 DMA; low risk for accumulation

Entry (Momentum Breakout) ₹2,120+ Break above local resistance with volume backing

Exit (Swing Target) ₹2,200 - ₹2,250 First resistance cluster from recent highs

Exit (Full Rally) ₹2,400+ If MACD continues rising & RSI reaches 60+

📘 Fundamental Insights

P/E (29.6) < Industry PE (34.0) ➤ relatively undervalued

PEG (1.38) ➤ moderately priced for growth

Zero debt, strong ROCE (25.8%) and ROE (21.7%) ➤ financially sound

Quarterly PAT improving, though modest ➤ implies stable profit base

🧭 Verdict

Trend: Trending upward after recent correction

Momentum: Bullish setup developing slowly

Pattern: Consolidation with upward bias; wedge formation

Technical Rating: 3.8

Would you like me to chart this visually or layer it with peer comparison in the pharma mid-cap space? There are some intriguing setups brewing. 💡📈

Edit in a page